Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/16/2026

1. SPY
2. ASML
3. PYPL
4. NVDA
5. JPM
6. AMZN
7. MSFT
8. SPCX
9. PNR
10. GS

Go back to Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Merck & Co. (NYSE: MRK) Delayed: 123.61 --0 (-0%)
Previous Close $123.61    52 Week High $65.46 
Open $123.61    52 Week Low $47.97 
Day High $123.61    P/E 84.09 
Day Low $123.61    EPS $1.47 
Volume 1,026